骨髓增生异常综合征的表观遗传靶向治疗现状  

Current status of epigenetic targeting treatment of myelodysplastic syndrome

作　　者：丁倩倩[1] 陈勤奋[1] 

机构地区：[1]复旦大学附属华山医院血液科,上海200040

出　　处：《上海医药》2013年第3期13-16,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：DNA甲基化和组蛋白去乙酰化是骨髓增生异常综合征(myelodysplastic syndrome,MDS)表观遗传学异常的重要组成部分,以逆转表观遗传改变为靶的的DNA甲基转移酶抑制剂和组蛋白去乙酰酶抑制剂成为近年MDS治疗的新方法。本文对MDS的表观遗传药物治疗现状进行综述,以期为MDS的治疗提供参考意见。DNA methylation and histone deacetylation are the important part of epigenetics abnormalities of myelodysplastic syndrome （MDS）. Currently epigenetically active drugs, including DNA methyltransferase inhibitors and histone deacetylase inhibitors, have become a novel targeting epigenetic modifiers therapy in MDS field. This review summarizes the current status of epigenetic treatment of MDS in order to provide reference information for clinical practice.

关 键 词：骨髓增生异常综合征 表观遗传学 DNA甲基化 组蛋白去乙酰化 

分 类 号：R551.3[医药卫生—血液循环系统疾病]